Related Experiment Video
Updated: Sep 15, 2025
Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model
Published on: February 3, 2021
Discovery of Novel c‑MET Inhibitors for Hepatocellular Carcinoma Using an Integrated Virtual Screening Approach
Rushan Fei1,2, Na Lin3,2, Xin Zhang4
1Department of Colorectal Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, No. 79, Qingchun Road, Hangzhou, Zhejiang Province 310003, China.
Abstract:
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related mortality worldwide, with the efficacy of current targeted therapies limited by drug resistance and adverse effects. The receptor tyrosine kinase c-MET has been identified as a promising target for HCC therapy due to its involvement in tumor progression, metastasis, and poor prognosis. However, no c-MET inhibitors have been approved for HCC treatment. This study integrates a multistep virtual screening workflow, incorporating molecular docking, machine learning-based predictions, and molecular dynamics simulations, to identify novel c-MET inhibitors with unique structural frameworks. Among several promising candidates, compound 10 exhibited potent c-MET inhibition and selective antiproliferative effects against the HCC cell line Hep3B. Further molecular dynamics simulations confirmed the binding stability of compound 10 with c-MET, highlighting key interactions that contribute to its inhibitory activity. These findings provide valuable insights into the development of c-MET inhibitors with potential therapeutic applications for HCC.
Insights
Researchers identified a novel compound (compound 10) that potently inhibits c-MET, a key target for hepatocellular carcinoma (HCC). This discovery offers a promising new avenue for developing effective HCC therapies with fewer side effects.
Area of Science:
- Oncology
- Pharmacology
- Computational Chemistry
Background:
- Hepatocellular carcinoma (HCC) is a major global cause of cancer mortality.
- Current HCC therapies face limitations due to drug resistance and adverse effects.
- The c-MET receptor tyrosine kinase is implicated in HCC progression and poor prognosis, representing a therapeutic target.
Purpose of the Study:
- To identify novel c-MET inhibitors for hepatocellular carcinoma (HCC) treatment.
- To explore unique structural frameworks for potential HCC therapeutics.
- To provide insights into developing targeted therapies for HCC.
Main Methods:
- A multistep virtual screening workflow was employed.
- Methods included molecular docking, machine learning predictions, and molecular dynamics simulations.
- Candidate compounds were evaluated for c-MET inhibition and antiproliferative effects.
Main Results:
- Compound 10 demonstrated potent c-MET inhibition.
- Compound 10 showed selective antiproliferative effects against the Hep3B HCC cell line.
- Molecular dynamics simulations confirmed stable binding of compound 10 to c-MET, revealing key interactions.
Conclusions:
- Compound 10 is a promising candidate for HCC therapy development.
- The identified compound exhibits potential for targeted inhibition of c-MET in HCC.
- This study offers valuable insights for designing novel c-MET inhibitors for HCC treatment.
